Oxymetazoline 0.1% shows promise in treatment of acquired blepharoptosis

Treatment with oxymetazoline 0.1%, was associated with improved superior visual field and upper eyelid elevation compared with treatment with vehicle a day 1 and day 14 in patients with acquired blepharoptosis, according to a study.

In this pooled analysis of 2 phase 3 trials, 304 participants with acquired ptosis and superior visual field deficit were randomized to daily self-administered eye drop treatment for 42 days with either oxymetazoline 0.1% (n = 203) or vehicle (n = 101). Overall, 198 patients in the treatment group and 98 in the vehicle group completed the studies.

Compared to vehicle, treatment with oxymetazoline 0.1% was associated with a significant increase in the mean number of points seen on the Leicester Peripheral Field Test and a significant increase in marginal reflex distance 1 from baseline.

In 31% of patients in the oxymetazoline 0.1% group treatment-emergent adverse events (TEAE) occurred, with 81% having a maximum TEAE intensity of mild, and 62% having no TEAE suspected of being treatment-related.

Reference
Slonim CB, Foster S, Jaros M, et al. Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration With Visual Field in Acquired Ptosis: A Pooled Analysis of 2 Randomized Clinical Trials. JAMA Ophthalmol. 2020;138(11):1168–1175. doi:10.1001/jamaophthalmol.2020.3812